SUN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SUN is not a good buy right now for an impatient buyer. The stock is short-term weak (down ~2.5% regular session) with momentum fading, options positioning shows heavy put open interest (defensive/hedged sentiment), and the most tangible near-term catalyst (TanQuid-related regulatory condition) adds execution risk. While analyst sentiment is broadly bullish (PTs up to $70) and the chart looks near-oversold (RSI6 ~31), there is no Intellectia buy trigger today and near-term pattern stats skew negative for the coming week—so the risk/reward is not compelling for an immediate entry.
Trend/momentum: Price weakness into post-market (57.58) after a -2.52% regular session suggests near-term selling pressure. RSI_6 at ~31 is near-oversold, which can support a bounce, but it is not a confirmed reversal signal by itself. MACD histogram is above zero but positively contracting, indicating bullish momentum is waning rather than accelerating. Moving averages are converging, consistent with consolidation/indecision rather than a strong trend. Levels: Provided pivots cluster near ~50 (Pivot 50.07; R1 50.92; S1 49.21), implying the next meaningful technical support zone is well below the current price—so if selling resumes, downside air-pocket risk is non-trivial. Quant pattern read-through: similar-pattern stats imply ~50% chance of a small down day next session and a negative bias over the next week (-4.54%), despite a more positive 1-month expectation (+4.09%).
Intellectia Proprietary Trading Signals
Analyst posture is supportive (multiple Buys/Overweight; Raymond James upgraded to Strong Buy with a $70 PT), which can underpin demand on pullbacks.
Broader midstream tailwinds cited by analysts (execution translating macro tailwinds into cash flow).
Upcoming earnings (Q4/Dec 2025 on 2026-02-17 pre-market) can serve as a catalyst if integration/volumes/margins surprise positively.
Event-driven/regulatory overhang: German government mandating the sale of a military-fuel-pipeline-related unit as a condition tied to the TanQuid acquisition introduces execution complexity, potential delays, and integration uncertainty.
Earnings volatility risk: Barclays highlighted refining exposure could add earnings volatility.
Near-term technical/quant bias is soft (momentum fading; similar-pattern data points to weakness over the next week).
No supportive near-term Intellectia trading signals (no AI Stock Picker or SwingMax entry).
Latest quarter: 2025/Q3. Revenue grew to $6.032B (+4.89% YoY), and gross margin improved to 8.07 (+41.08% YoY), indicating better profitability at the gross level. However, net income fell to $88M (-351.43% YoY) and EPS to $0.64 (-346.15% YoY), showing a sharp bottom-line deterioration (likely influenced by non-operating items, acquisition/integration impacts, or comparables). Net result: top-line and gross margin trends are positive, but earnings quality/volatility is a concern heading into the next report.
Recent trend: Street sentiment has turned more bullish into 2026. Raymond James (2026-01-05) upgraded to Strong Buy (from Outperform) and kept a $70 target; earlier RJ (2025-11-05) raised PT to $70 from $67. Stifel (2025-11-07) maintained Buy with a modest PT trim to $61 while incorporating Parkland acquisition. Barclays (2025-11-17) reinstated Overweight with a $57 PT, noting scale/diversification benefits but flagging refining-driven volatility.
Wall Street pros: execution momentum, diversified asset base, volume trends, and potential upside from optimization/integration/M&A. Cons: earnings volatility (refining exposure), integration/execution risk, and event/regulatory conditions that may constrain deal benefits.
Influential trading check: Hedge funds and insiders are reported neutral with no significant recent trends. No recent Congress trading data is available, and no notable politician/influencer buy/sell activity is provided in the dataset.
